Camp4 Therapeutics Corporation (CAMP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - CAMP4 is focused on using antisense oligonucleotides to selectively increase gene expression, positioning itself as a product company with a powerful platform [3]. Key Program - The flagship program of CAMP4 targets SYNGAP1-related disorders, a genetic haploinsufficiency CNS disorder with no approved treatments or disease-modifying therapies currently in development [4]. - The lead program for SYNGAP is CMP-002, which aims to be the first to enter clinical trials with a disease-modifying approach [4]. Market Potential - There are tens of thousands of patients suffering from SYNGAP around the world, indicating a significant unmet medical need [4].